Could a diabetes drug ease two heart conditions at once?
NCT ID NCT06027307
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 24 times
Summary
This study tests a drug called enavogliflozin in 541 adults with heart failure and a leaky heart valve (tricuspid regurgitation). Participants take the drug or a placebo for 18 months. The goal is to see if the drug lowers the risk of heart-related death, hospital stays, or worsening of the valve leak. This is a phase 3 trial, meaning it is in the final testing stage before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Inha University Hospital
Incheon, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Yonsei University Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.